Bio-Rad Laboratories (NYSE:BIO.B) Releases Earnings Results

Bio-Rad Laboratories (NYSE:BIO.B) announced its quarterly earnings data on Wednesday. The company reported $2.65 earnings per share (EPS) for the quarter, Zacks reports. Bio-Rad Laboratories had a net margin of 8.59% and a return on equity of 3.54%.

Bio-Rad Laboratories Price Performance

Shares of BIO.B stock remained flat at $379.50 during trading hours on Wednesday. 12 shares of the stock were exchanged, compared to its average volume of 38. Bio-Rad Laboratories has a 12 month low of $244.54 and a 12 month high of $379.50. The business has a fifty day moving average price of $366.64 and a two-hundred day moving average price of $311.96. The firm has a market cap of $10.15 billion, a P/E ratio of 46.00 and a beta of 1.00. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.33 and a current ratio of 3.14.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (NYSE: BIO.B) develops, manufactures and markets products and systems used in life science research and clinical diagnostics. The company serves academic, pharmaceutical, biotechnology, industrial and healthcare customers with laboratory instruments, reagents, consumables, software and related services.

Its life science portfolio includes technologies for genomics, digital PCR, protein analysis, chromatography, electrophoresis, cell biology and imaging. Bio-Rad’s clinical diagnostics business provides systems and reagents used in areas such as diabetes monitoring, blood typing, quality control, infectious disease testing and autoimmune diagnostics.

Founded in 1952 by David and Alice Schwartz, Bio-Rad is headquartered in Hercules, California, and serves customers through operations and distribution networks in North America, Europe, Asia-Pacific and other international markets.